Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands.
Harold B WolffElisabeth M P SteeghsZakile A MfumbilwaHarry J M GroenEddy M AdangStefan M WillemsKatrien GrünbergEd M D SchuuringMarjolijn J L LigtenbergBastiaan B J TopsVeerle M H CoupéPublished in: JCO precision oncology (2022)
NGS-based parallel testing is diagnostically superior over single-gene-based sequential testing, as it is cheaper and more effective than sequential testing. Parallel testing remains cost-effective with an incremental cost-effectiveness ratio of 69,614 €/QALY upon inclusion of therapeutic costs and long-term outcomes.
Keyphrases